Full-Time

Senior Scientist

DMPK

General Proximity

General Proximity

11-50 employees

Seed-stage platform for induced proximity drugs

No salary listed

San Francisco, CA, USA

In Person

On-site role in San Francisco; no remote option stated.

PhD

Category
Biology & Biotech (1)

Get referred to General Proximity

See people who can refer or advise you

Requirements
  • PhD in pharmacokinetics, pharmaceutical sciences, or a related discipline.
  • A minimum of 3 years of industry experience in DMPK, spanning drug discovery and development, with a track record of contributing to small molecule programs.
  • Demonstrated ability to work independently and collaborate effectively within cross-functional project teams.
  • Hands-on expertise in in vitro ADME and in vivo PK, with the ability to translate data into actionable drug discovery insights.
  • Proficiency in PK data analysis (Phoenix WinNonlin or equivalent) and familiarity with PBPK/PK-PD modeling platforms (Simcyp, GastroPlus, or equivalent).
  • Experience contributing to IND-enabling DMPK studies and authoring study reports.
  • Working knowledge of FDA, EMA, and ICH guidance relevant to DMPK (DDI, MIST, M9/M10, bioanalytical validation).
  • Strong communication and presentation skills, with the ability to clearly convey DMPK science to cross-functional teams.
  • Hands-on experience with bioanalytical activities, including LC-MS/MS method development in support of DMPK studies.
  • Working knowledge of clinical pharmacology principles, including FIH dose projection, DDI risk assessment, and exposure–response analysis, sufficient to support drug development through early clinical stages.
Responsibilities
  • In Vitro ADME: Design, execute, and interpret in vitro ADME studies, including metabolic stability, CYP inhibition/induction, plasma protein binding, permeability (Caco-2/MDCK), solubility, and transporter assays.
  • Contribute to in vitro–in vivo correlation (IVIVC) analyses to inform candidate selection and advance structure–activity/property relationships.
  • Interpret metabolic soft spot and MetID data, translating findings into actionable guidance for medicinal chemistry teams.
  • Support CRO relationships for outsourced ADME studies, including scientific oversight of study execution and data quality review.
  • Bioanalytical Sciences: Support bioanalytical activities for the portfolio, including CRO-performed LC-MS/MS method development for small molecules and their metabolites across biological matrices.
  • Help ensure GLP-compliant bioanalytical practices for IND-enabling studies and monitor regulated bioanalysis timelines and data quality through CRO partners.
  • Contribute to fit-for-purpose bioanalytical approaches for induced proximity molecules, including strategies for quantifying bifunctional compounds and target engagement biomarkers.
  • In Vivo Pharmacokinetics: Design and support in vivo PK studies across rodent and non-rodent species, including study design, data interpretation, and cross-program learnings.
  • Perform high-quality PK data analysis (NCA and compartmental) using Phoenix WinNonlin or equivalent, ensuring accurate reporting and data integrity.
  • Integrate PK data with pharmacology and toxicology readouts to inform candidate progression criteria and target product profiles.
  • Coordinate with CROs for in vivo studies, tracking scope, timelines, and scientific deliverables.
  • PK/PD Modeling & Simulation: Perform PK/PD modeling and simulation, including PBPK modeling (Simcyp, GastroPlus) and allometric scaling to support human PK prediction.
  • Apply quantitative pharmacology approaches to support translational decision-making, FIH dose selection, and clinical dose range prediction.
  • Use modeling and simulation to inform go/no-go decisions and communicate DMPK findings to project teams.
  • Present DMPK modeling results in cross-functional project team meetings.
  • Regulatory & IND-Enabling Work: Support DMPK execution for IND-enabling programs, including study design, drafting of study reports, and data package delivery.
  • Contribute to DMPK sections of IND and CTA submissions; author and review relevant study reports and document sections.
  • Support preparation of DMPK materials for interactions with regulatory agencies, including briefing documents.
  • Maintain working knowledge of current regulatory guidance (DDI, MIST, bioanalytical method validation, ICH M9/M10) and apply evolving standards.
  • Collaboration & Cross-Functional Contribution: Contribute to DMPK team goals and priorities in alignment with company objectives and pipeline evolution.
  • Serve as an active member of cross-functional project teams, contributing DMPK input to program planning and decision-making.
  • Support DMPK input for scientific evaluations and collaborations as needed.
  • Support clinical pharmacology activities as programs advance toward IND, including FIH dose projections, DDI risk assessment, and exposure–response analysis; contribute to clinical pharmacology sections of regulatory documents.
  • Help track CRO spend and study timelines in alignment with program milestones.
  • Author and present scientific findings through peer-reviewed publications, conference abstracts, and posters; contribute to General Proximity’s scientific credibility and platform visibility in the induced proximity field.
Desired Qualifications
  • Experience in a startup or early-stage biotech environment
  • Experience contributing to a small molecule program advancing toward or through IND
  • Experience with novel modalities such as TPD, molecular glues, or PROTACs
  • Familiarity with AI/ML-based ADME prediction tools and an interest in integrating computational approaches (e.g., ML-driven metabolic stability or permeability models) into the DMPK workflow alongside established platforms such as Simcyp and GastroPlus

Preparing a concise company summary based on provided description.

Company Size

11-50

Company Stage

Seed

Total Funding

$16.1M

Headquarters

San Francisco, California

Founded

2019

Get referred to General Proximity

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FreeMind and Daewoong invested on May 4, 2026, adding strategic Asian commercial reach.
  • ARPA-H and NCI grants de-risk non-dilutive financing for 2026 preclinical work.
  • General Proximity raised $28 million total and expanded July 2026 hiring momentum.

What critics are saying

  • General Proximity still has no public IND or named clinical asset as of July 2026.
  • Platform biology remains unproven clinically; Daiichi Sankyo and Daewoong can walk away.
  • Larger rivals like Revolution Medicines, Nurix, and C4 Therapeutics crowd induced-proximity oncology.

What makes General Proximity unique

  • OmniTAC scans effectors broadly, not one degradation pathway, widening target access.
  • Daiichi Sankyo signed a multi-target oncology collaboration on November 12, 2025.
  • General Proximity says its lead program is internally discovered and best-in-class.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

15%
Noah Business Intelligence
Jul 6th, 2026
General Proximity Bio raises $28M across seed and pre-Series A for induced-proximity drug platform

San Francisco biotech General Proximity Bio has secured notable early-stage investment for its induced-proximity medicine platform. The company emerged from stealth in January 2025 with $16 million in seed funding led by Felicis Ventures, alongside Y Combinator, age1, and other investors. It subsequently closed an oversubscribed $12 million pre-Series A round, attracting strategic investment from Daewoong Pharmaceutical and FreeMind Investments. General Proximity also received non-dilutive support through grants from ARPA-H and the National Cancer Institute. The platform targets proteins traditionally considered difficult to drug, focusing on cancer, cardiometabolic disease, neurodegeneration, and longevity. The company remains preclinical with no public IND filing or lead asset. Scientific challenges in proximity-based drug design include selectivity, pharmacokinetics, oral delivery, and off-target effects. General Proximity is pursuing a platform approach rather than developing a single near-term product.

Yonhap Infomax
Apr 30th, 2026
Daewoong Pharmaceutical invests in US biotech General Proximity for induced proximity drug development

Daewoong Pharmaceutical has invested in US biotech firm General Proximity alongside venture capital fund Freemind Investment to collaborate on new drug development. The investment amount was not disclosed. The partnership aims to secure "induced proximity" technology, a next-generation drug development method that regulates protein function by bringing disease-related proteins and regulatory proteins together. This approach differs from conventional methods that required drugs to fit precisely into specific binding sites, potentially expanding treatment options for previously inaccessible proteins. Founded in 2019, General Proximity possesses a platform for discovering induced proximity therapeutics based on Effectome scanning technology. The company is developing new drug pipelines in oncology, cardiovascular and metabolic diseases, and neurodegenerative diseases.

Business News Today
Nov 12th, 2025
General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology

General Proximity inks Daiichi Sankyo deal to push precision small molecules into oncology. General Proximity partners with Daiichi Sankyo to develop proximity-based cancer drugs using OmniTAC. Discover how this biotech is redefining drug discovery. General Proximity, a San Francisco-based biotechnology company developing proximity-induced medicines, has signed a strategic multi-target collaboration with Daiichi Sankyo Co., Ltd. to co-develop cancer treatments using its proprietary OmniTAC discovery platform. The partnership, routed through the Daiichi Sankyo Research Institute in Boston, will focus on identifying first-in-class therapeutic candidates capable of modulating proteins traditionally viewed as "undruggable" in oncology.

VCNewsDaily
Jan 3rd, 2025
General Proximity Raises $16M Funding

General Proximity, a biotech platform company, has emerged from stealth with $16M in funding. The oversubscribed seed round was led by Aydin Senkut of Felicis, with participation from Y Combinator, age1, Modi Ventures, Wilson Sonsini, and angel investors like Jeff Dean and Ben Mann. The funds will accelerate the development of treatments targeting undruggable proteins related to cancer, cardiometabolic disease, neurodegeneration, and longevity.

PR Newswire
Jan 3rd, 2025
General Proximity Raises $16M for Undruggable Targets

General Proximity has emerged from stealth with $16M to develop treatments for undruggable proteins linked to cancer, cardiometabolic disease, neurodegeneration, and longevity using its OmniTAC platform. The $8M seed round was led by Aydin Senkut at Felicis. Other investors include Y Combinator and Jim Dahl. The company aims to revolutionize drug discovery with a potential market exceeding $250 billion annually.